Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 23.02.2026 4 BJU Int 1 BMC Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 1 Clin Cancer Res 2 Eur Radiol 2 Eur Urol 2 Int J Radiat Oncol Biol Phys 3 Int J Urol 1 J Nucl Med 2 Lancet Oncol 1 Mol Ther Oncol 1 Oncogene 1 Oncol Rep 1 PLoS Comput Biol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. BUHAS BA, Uleri A, Katzendorn O, Salin A, et al
   Transition to a digital perioperative pathway for robot-assisted radical prostatectomy: impact on patient outcomes and adherence.
   BJU Int. 2026;137:473-479.
   PubMed         Abstract available
   
   
2. DE LA CALLE CM, Baras AS, Lotan TL
   Digital pathology-based artificial intelligence algorithms in prostate cancer: inside the 'black box'.
   BJU Int. 2026 Feb 16. doi: 10.1111/bju.70164.
   PubMed         Abstract available
   
   
3. AL-NADER M, Kesch C, Mahmoud O, Hadaschik BA, et al
   Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer.
   BJU Int. 2026 Feb 16. doi: 10.1111/bju.70167.
   PubMed         Abstract available
   
   
4. NATHAN A, Parry MG, Cook A, Mayne E, et al
   Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.
   BJU Int. 2026 Feb 17. doi: 10.1111/bju.70179.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. MALYGINA H, Salazar Zuniga B, Auerbach H, Ries M, et al
   Clinical experience with an online adaptive radiotherapy for prostate cancer: successful treatment time optimization.
   BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15768.
   PubMed         Abstract available
   
   

   
   Cancer

6. VENKATESWARAN S, Mantena RV, Willmann J, Zhang YH, et al
   Not all progression is equal.
   Cancer. 2026;132:e70311.
   PubMed         Abstract available
   
   

   
   Cancer Lett

7. XIE Z, Li S, Yang J, Zhang Z, et al
   SNHG18 deficiency reprograms arginine metabolism to foster an immunosuppressive microenvironment in prostate cancer bone metastasis.
   Cancer Lett. 2026;644:218326.
   PubMed         Abstract available
   
   

   
   Cancer Res

8. THIENGER P, Akhoundova D, Rubin MA
   Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.
   Cancer Res. 2026;86:827-829.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. MCBRIDE SM, Spratt DE, Kollmeier M, Abida W, et al
   Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 Study.
   Clin Cancer Res. 2026 Feb 19. doi: 10.1158/1078-0432.CCR-25-3746.
   PubMed         Abstract available
   
   

   
   Eur Radiol

10. AGROTIS G, Jaderling F, Lakhani A, Moreira ASL, et al
    ESR Essentials: MRI-based T-staging in prostate cancer-practice recommendations by the European Society of Urogenital Radiology.
    Eur Radiol. 2026 Feb 20. doi: 10.1007/s00330-026-12397.
    PubMed         Abstract available
    
    
11. STANZIONE A, Cuocolo R
    Less is more? Strategies for sustainable prostate cancer screening in the era of MRI.
    Eur Radiol. 2026 Feb 19. doi: 10.1007/s00330-025-12297.
    PubMed        
    
    

    
    Eur Urol

12. STRIEDER DE OLIVEIRA G, Altmayer S, Torri GB, Prediger JE, et al
    Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis.
    Eur Urol. 2026 Feb 16:S0302-2838(26)00058-8. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
13. BANCROFT EK, Page EC, McHugh J, Thomas S, et al
    Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
    Eur Urol. 2026 Feb 18:S0302-2838(26)00057-6. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

14. SHEN J, Chen RC, Sayan M, Shen X, et al
    Changes over time in total Medicare costs for active surveillance versus radiotherapy in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2026 Feb 14:S0360-3016(26)00387.
    PubMed         Abstract available
    
    
15. VARGAS CE, Voss MM, Dodoo C, Wong W, et al
    Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer with High-Risk Features Following Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2026 Feb 17:S0360-3016(26)00328.
    PubMed         Abstract available
    
    

    
    Int J Urol

16. KOBAYASHI S, Shiota M, Onozawa M, Taguchi S, et al
    To Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.
    Int J Urol. 2026;33:e70381.
    PubMed         Abstract available
    
    
17. TANABE K, Yoshida S, Chen W, Yajima S, et al
    Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup Results.
    Int J Urol. 2026;33:e70384.
    PubMed         Abstract available
    
    
18. TAKAHASHI H, Fukuokaya W, Muramoto K, Katsumi K, et al
    Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70369.
    PubMed         Abstract available
    
    

    
    J Nucl Med

19. PEPIN A, Doucette A, Narayan VK, Maxwell KN, et al
    Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Feb 19:jnumed.125.270757. doi: 10.2967/jnumed.125.270757.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

20. CORREA RJM, Bauman GS
    Stepping through the PORTAL: moving toward personalised management of oligorecurrent prostate cancer.
    Lancet Oncol. 2026 Feb 16:S1470-2045(26)00003.
    PubMed        
    
    
21. SOETERIK TFW, Miszczyk M, Peters M, Bilski M, et al
    Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00717.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

22. HU B, Wu P, Zheng L, Yang H, et al
    Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption.
    Mol Ther Oncol. 2026;34:201133.
    PubMed         Abstract available
    
    

    
    Oncogene

23. LI H, Song Y, Cong Y, Wang C, et al
    YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis.
    Oncogene. 2026 Feb 18. doi: 10.1038/s41388-026-03696.
    PubMed         Abstract available
    
    

    
    Oncol Rep

24. LAKSHMI PSV, Parashar J, Biswas B, Ummanni R, et al
    Hypoxia?induced miR?135b?5p promotes neuroendocrine differentiation of prostate cancer cells through HIF1AN?HIF1alpha axis.
    Oncol Rep. 2026;55:74.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

25. WANG Y, Zang C, Li Z, Guo CC, et al
    A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics.
    PLoS Comput Biol. 2026;22:e1013956.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum